Foghorn Therapeutics (FHTX) Plunges 49% as Eli Lilly Partnership Collapses

Key Takeaways

• Foghorn Therapeutics shares plummeted 49% to $1.84 following Eli Lilly’s decision to terminate their collaborative partnership.
• Both companies agreed to discontinue FHD-909 development after Phase 1 trial results failed to meet expectations.
• A second joint program targeting SMARCA2 degradation is also being terminated.
• The biotech firm plans to reduce its workforce by approximately 40% as part of cost-reduction efforts.
• Cash reserves are projected to last through late 2029 following restructuring measures.

Shares of Foghorn Therapeutics experienced a devastating decline Thursday after the biotechnology company revealed that its collaboration with pharmaceutical giant Eli Lilly had been terminated. The stock plunged 49% to $1.84 when trading activity resumed, representing the company’s largest single-session decline ever recorded.

Foghorn Therapeutics Inc., FHTX

Shares were temporarily halted prior to the announcement. Once the market reopened, a wave of selling pressure hit the stock.

The biotechnology firm’s market capitalization now stands at approximately $212 million. This represents a dramatic decline for a company that previously maintained a strategic alliance with one of the pharmaceutical industry’s leading players.

The collaborative partners mutually decided against advancing FHD-909 into expanded clinical development following completion of its Phase 1 dose escalation study.

FHD-909 was designed as an oral small molecule inhibitor targeting the SMARCA2 protein. The therapeutic approach utilized synthetic lethality principles, specifically designed to exploit particular genetic vulnerabilities in tumor cells.

Reasons Behind Program Termination

Chief Executive Adrian Gottschalk explained that the compound successfully engaged its intended molecular target. The safety profile also appeared acceptable, even when administered at doses exceeding those predicted by preclinical research.

However, clinical efficacy proved insufficient. Gottschalk noted that the underlying biology of the SMARCA2/4 synthetic lethal relationship failed to produce therapeutic responses robust enough to warrant continued development.

This represents a significant setback after extensive research efforts. The implications extend beyond a single experimental therapy.

Both organizations confirmed that an additional cancer-focused collaboration centered on a Selective SMARCA2 degrader will also be discontinued. Foghorn indicated no expectation of future collaborative initiatives with Lilly.

The original partnership was established in December 2021, when Lilly’s Loxo Oncology division agreed to terms including $300 million in initial payments plus an $80 million equity investment at $20 per share.

While those agreement terms appeared favorable for Foghorn initially, current trading levels represent a substantial decline from that $20 valuation.

Foghorn’s Path Forward

Following the partnership dissolution, Foghorn has initiated significant cost-containment measures. The organization plans to reduce headcount by nearly 40% while restructuring its operational framework.

Company leadership projects these strategic actions will extend available capital resources through the latter portion of 2029. This timeline provides sufficient runway to sustain ongoing pipeline development efforts.

Foghorn stated it will concentrate resources on wholly-owned proprietary programs moving forward. This portfolio encompasses a Selective EP300 degrader, a Selective CBP degrader, and an oral therapeutic program targeting immunology and inflammatory conditions.

The organization will also maintain emphasis on its induced proximity discovery platform as a strategic priority. These initiatives operate independently of Lilly’s financial support.

Eli Lilly’s stock experienced minimal impact from the announcement. Shares declined approximately 2%, representing an insignificant fluctuation for the pharmaceutical giant.

For Foghorn, the consequences are far more substantial. The biotech company must now rely primarily on internal capital resources and a significantly reduced organization to advance its clinical pipeline through the coming years.